| I N TR ODU C TI ON
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children below age of 14 years. 1 This is a heterogeneous disease as
shown by variable gene expression in many studies. [2] [3] [4] With advances in treatment through large-scale clinical trials, the long-term survival rates for childhood ALL were approaching 90% in many developed countries. 5 However, treatment-related mortality was still high in the developing countries. 6 With the improvement in socio-economic condition and the establishment of the national insurance system, more chil- This study might establish a platform for future national based treatment strategy, 7 and serve as a model for future similar studies for other types of childhood cancer and severe hematological disorders in the country.
The CCLG-ALL 2008 Study was based on BFM ALL treatment backbone with some modifications to reduce the treatment-related mortality. Here, we reported the treatment results of this trial involving 2231 children from China.
| P A TI E NT S A ND M E TH ODS

| Study design and participants
In this multicenter clinical trial, participation centers were hospitals with experience in treating children with ALL, equipped with dedicated facilities and personnel for diagnosis and treatment of ALL in China.
The 10 centers from eight cities were either hematology departments of children's hospitals or hematology divisions of pediatric departments in university general hospitals. The participation centers followed the unified inclusion and exclusion criteria. All previously untreated patients presented to the ten centers were recruited. The five hospitals in Hong Kong were grouped as one institution because of small number of patients.
Between April 1, 2008 and December 31, 2012, a total of 2231 patients under age of 18 years with newly diagnosed ALL were recruited into the trial (Supporting Information Figure S1 ). The clinical study was approved by institutional ethical committees of all participating hospitals, and patients were only recruited when the parents or legal guardian provided written informed consent for the research study. Separate informed consent forms were obtained at the time of randomization of the maintenance arms. Standardized informed consent forms were applied in all participating centers. Assents from the patients were also obtained when the patients were old enough to understand the treatment and research study.
| Procedures
The treatment strategy of CCLG-ALL 2008 study was shown in Figure   1 , and the details of the treatment elements were provided in Supporting Information Table S1 . ALL were diagnosed if at least 25% lymphoblasts were present in the bone marrow (BM). Immunophenotypic and karyotypic features of leukemic cells were determined according to standard techniques. 8, 9 Cytogenetic study for TEL-AML1, BCR-ABL1, E2A-PBX1, and MLL rearrangement was tested by karyotyping, fluorescence in situ hybridization (FISH) and/or polymerase-chained reaction (PCR) methods. 10 The central nervous system (CNS) status was defined 
| Statistical analysis
Event-free survival (EFS) was estimated from date of diagnosis until date of one of the following events: relapse, refractory disease, second malignancy or death from any reason. Overall survival (OS) was defined as time from diagnostic date through the date of death due to any reasons.
Relapse-free survival (RFS) was estimated from the date of diagnosis until the date of relapse at any site. If no event occurred, the observation time was censored at the last follow-up. Patients abandoned treatment without serious toxicities or lost to follow-up in complete remission (CR)
were censored at the last contact. Survival rates were estimated by the Kaplan-Meier method, 15 and differences in OS and EFS were compared with two-tailed log-rank test. 16 Cox proportional hazards model was used for multivariate analyses. 17 Cumulative incidence of relapse (CIR)
for competing events was constructed by the method of Kalbfleisch and Prentice, 18 and compared using Gray's test. 19 The Fisher's exact test was 
| RE S U L TS
| Patients' characteristics
A total of 2231 out of 2427 (91.9%) patients with newly diagnosed ALL were enrolled in this study (Supporting Information Table S2 ).
Among the ten hospitals, four hospitals recruited 100% of patients (high recruitment group, n 5 1574), and the other six hospitals enrolled 70.2% to 84.7% of patients (low recruitment group, n 5 657). The four centers with high recruitment included not only the developed areas such as Beijing and Hong Kong, but also the less economically developed area in southwestern China, Chongqing. Meanwhile, the low recruitment group also consisted of several centers in Beijing and 
| Treatment outcome
At a median follow-up of 47.3 months (range 0-85.8 months), the estimate of 5-year OS and EFS for the whole group were 85.3% 6 0.8% and 79.9% 6 0.9%, respectively ( Figure 2 ). Univariate predictors of outcome were presented in Table 1 . CNS status was identified as a significant predictor of survival, and the outcome for CNS2 or CNS3 was inferior to CNS1 (P < .001). Analysis of survival was also performed according to the cytogenetic subtypes (Supporting Information Figure   S2 ). The TEL-AML1 fusion was detected in 16.3% of patients, and was associated with the best outcome (5y-OS: 93.0% 6 1.5%; 5y-EFS:
89.5% 6 1.8%). BCP-ALL patients with MLL rearrangement had 5-year OS and EFS rates similar to those of patients with T-cell ALL. As the tyrosine kinase inhibitor was not included for treatment of BCR-ABL1 1 ALL in the protocol, the outcome of patients with BCR-ABL1 was the worst among the various subgroups, with a 5y-OS of 53.7% 6 5.8%
and 5y-EFS of 48.0% 6 5.5%. With the exception of infants and posttransplantation toxicities, there was no obvious change in the prognostic influence of those factors. After exclusion of the 15 infants in the analysis, the 5-year EFS and OS for the 2216 patients over age of one year were 80.2% 6 0.9% and 85.4% 6 0.8%, respectively.
| Events
Treatment outcome was summarized in Eighty-nine patients (4.0%) in CCR without serious toxicities gave up treatment because of financial difficulty, and 54% of them during early intensification phase and 35% during consolidation phase.
CIR at five years (5y-CIR) was 15.3% 6 0.9%. The most frequent site of relapse was BM. The 5y-CI of isolated CNS relapse and combined relapses with CNS involvement was 1.7% 6 0.3% and 1.8% 6 0.3%, respectively. Only one patient with IR risk developed an acute myeloid leukemia as a secondary neoplasm after first CR of 21.6 months.
| Toxicity
Death during induction happened in 36 patients (1.6%), 27 due to infection and nine due to bleeding. Death due to nonrelapse causes after archiving CR happened in 64 patients (2.9%): 21 at early intensification, 14 at consolidation, 10 at delayed intensification, 11 during maintenance and another eight after stem cell transplantation. The cause of remission death was mainly attributed to severe infections (73.4%), and other causes included bleeding and multiple organ failure.
Graft-versus-host disease was the main cause of death after transplant.
Septicemia was the major cause of treatment-related mortality, and infective pathogen was identified in 58.8% of these died cases (47/80). The majority were bacterial infections (59.6%), 25.5% were fungal, and 14.9% were viral. Other significant treatment-related toxicities included seizures, pancreatitis, thrombosis and osteonecrosis.
| Comparison of the MRD group and non-MRD group
In the two centers piloting MRD stratification (the MRD group, n 5 855), Figure   S3 and Table S4 ), OS was similar in both groups (86.5% 6 1.2% vs 84.6% 6
1.0%, P 5 .273), but EFS was significantly better in the MRD group (82.4% 6 1.4% vs 78.3% 6 1.2%, P 5 .038). The CIR was significantly lower in the MRD group (10.7% 6 1.3% vs 18.0% 6 1.2%, P < .001).
We observed that the MRD group had more patients with favorable subtypes as compared with non-MRD group (Supporting Information well as the MRD-based classification were used as covariates, all of which reached a P value <0.1 in the respective univariate analysis.
Adjusted for these factors, the MRD-based classification remained as an independent prognostic factor for both RFS and EFS. and EFS (75.0% 6 6.8% vs 58.4% 6 2.7%, P 5 .065) than the chemotherapy HR group (Supporting Information Figure S4 ). The CIR in HSCT group was 10.0% 6 2.3%, which was significantly lower than those HR patients treated with chemotherapy (29.7% 6 6.6%, P 5 .002). Details of randomization for maintenance in SR and IR patients will be reported separately. There was no statistical difference in the outcome of the two arms (Supporting Information Figure S5 ).
| D ISC USSION
This was the largest multicenter clinical trial in childhood ALL in China.
The previously reported single center studies in China were small size and some of them had incomplete recruitment, mainly due to high treatment cost. 20, 21 From mid-2000s, the China government started to implement insurance coverage for children with serious illnesses, and then more families could receive treatment according to standard care. 22 With this background, this multicenter study group was established. Six centers could not achieve 100% enrollment, however we did not observe any significant difference in the patients' demographic features between the high and low recruitment groups, which suggested selection bias as unlikely.
In this study, we confirmed some special biological features in Chinese. T-ALL was present in 8.4% in this study, and the previous studies in Chinese reported 8.1% to 9.7% incidence of T-ALL. 23, 24 The BFM 2000 study reported that 13.2% of non Ph 1 patients had T-ALL, 25 and CCG 21900 series enrolled 15.9% of ALL with T-lineage. 26 TEL-AML1 incidence in this study was 16.3%, which was lower than the western reports of 21%. 27 We noticed that only 6.3% of patients in Chongqing area (the less economic developed region) were TEL-AML1 positive.
The presence of TEL-AML1 in childhood ALL might be related to economic development. Further studies to observe the trend in China would be interesting during the era of rapid development.
As compared with the ALL IC-BFM 2002 study, 28 our current study had a similar chemotherapy backbone but with reduced intensity in SR. The course of early intensification for the SR group was shortened by 50% from 4 weeks to 2 weeks, and the dose of delayed intensification was reduced by around 25%-33% compared to BFM protocol II. The EFS and CIR for the SR group were better than that of ALL IC-BFM 2002 (87.9% vs 81.0%; 9.7% vs 14.4%).The incidence of death in CR was also lower in SR patients (1.5% vs 2.8%). Patients in HR group in this study adopted a more intensive maintenance treatment of St.
Jude Children's Research Hospital. 29 The OS and EFS of 68.1% and 59.9% for HR are encouraging. This study adopted strict eligibility criteria for allogeneic HSCT during first CR, and the outcomes of transplanted patients were good. The prophylaxis of CNS leukemia by nonradiation approach was also successful in this study with low CNS relapse rate.
Treatment related mortality was an important cause of treatment failure in developing countries. 30, 31 In this study, death happened in 1.6% during induction and 2.9% during remission, which was higher than that of developed countries. 32 Infection was the most important cause of death and should be the target for future improvement. Early recognition and intervention for infection may reduce the remission death. Abandonment of treatment was another important cause of treatment failure in developing countries. In this study, 4% of patients abandoned treatment after achieved remission, which was already much lower than previously reported. 23 Adopting less intensive treatment and implementing insurance cover would be the most effective strategy.
MRD was widely used for early response assessment but requires standardization and quality control. 33 MRD monitoring was piloted in two centers for treatment modification in this study. MRD monitoring had upstaged about 30% of patients from SR to IR/HR to receive a more intensive chemotherapy regimen. The MRD-SR group then became a real "low risk" group with 2.8% CIR despite a reduced intensity SR regimen. MRD-IR constituted the largest proportion of whole group (55.1%), and the CIR could be kept at a relatively low level of 11.3%. MRD stratification was demonstrated to have significant improvement in EFS and CIR. To our knowledge, this was the only study comparing two groups of patients receiving or not receiving MRD guided treatment within the same treatment protocol.
There were several limitations in this study. The recruitment of patients in some centers was not complete and MRD testing could only be applied in two centers. Data collection was also a big challenge as most centers did not have designated data managers. Fortunately the study received grant from government and charity, and honorarium could be offered to staff working off duty to collect data. Despite the above limitation, all the participating centers showed improvement of treatment outcome, and also could follow a standard treatment protocol in the participating centers.
In conclusion, multicenter clinical study was feasible in China. The outcome of this study was satisfactory with acceptable morbidity and mortality. SR group could be cured with less intensive treatment and CNS relapse could be prevented by chemotherapy based treatment.
MRD guided treatment appeared to improve EFS and would be extended to all hospitals.
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